OrisDX is a seed-stage biotech company with proven scientific pedigree and early validation. The company was formed based on a decade of research in the field of liquid biopsy and cancer genomics at the University of Chicago and Johns Hopkins University by top physicians and scientists. The company received a $250,000 Accelerator Award from the Chicago Biomedical Consortium in October 2025 to advance commercialization of its HPV oral cancer detection platform.
Cyborg Score Rationale
OrisDX addresses a genuine unmet clinical need with science-backed technology and accomplished founders, but remains in early stage with minimal commercialization signals. Small team size (5-9 employees), no disclosed revenue, and early-stage funding ($4.92M raised) present execution and market-adoption risks typical of pre-commercial diagnostic startups.
Top Insights
OrisDX has raised $4.92M to date and secured a $250K non-dilutive grant (October 2025), signaling investor and institutional confidence in the HPV detection technology but underscoring early-stage capital constraints for commercialization.
The company operates in an uncontested diagnostic niche: no ADA-endorsed salivary oral cancer test exists, positioning OrisDX as a first-mover if clinical evidence supports adoption in dental and primary care settings.
Scientific team includes co-founders with Johns Hopkins cancer genomics track records and 10+ years of liquid biopsy research, mitigating technology risk but leaving go-to-market and reimbursement execution as primary value drivers.
Named Competitors
Luminance Diagnostics — Early cancer detection through salivary biomarkers
DynaLab Genomics — Oral cancer screening via saliva-based molecular diagnostics
Recent Developments
(October 2025) Received $250K Chicago Biomedical Consortium Accelerator Award
(January 2025) Company formation narrative and University of Chicago partnership details publicly disclosed